Female reproductive organ cancer
MONDO:0001416A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.
Also known as: cancer of female reproductive organ, female reproductive cancer, female reproductive organ cancer, gynecologic cancer, malignant female reproductive organ neoplasm, malignant female reproductive system neoplasm, malignant female reproductive system tumor, malignant female reproductive system tumour
4573 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 2029 trials in this tab.
-
DNA vaccine aims to train immune system against HPV-Linked cervical lesions
⭐️ VACCINE ⭐️ Recruiting nowThis phase 1 trial tests a DNA vaccine designed to target HPV16, a virus that can cause high-grade cervical lesions (CIN2/3). The vaccine is given by injection into the muscle followed by a mild electrical pulse to help cells take up the DNA. The study includes both HIV-negative …
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 04, 2026 00:00 UTC
-
Could probiotics help ovarian cancer patients on chemo?
Disease control Recruiting nowThis study tests whether taking probiotic supplements can improve the gut and vaginal microbiome in women with advanced or recurrent ovarian cancer who are receiving platinum-based chemotherapy. About 161 participants will be randomly assigned to receive either probiotics or a pl…
Phase: EARLY_PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control Recruiting nowThis study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New hope for advanced cancer: APR-1051 enters first human trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…
Phase: PHASE1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Could existing cancer drugs tackle rare tumors? new trial aims to find out
Disease control Recruiting nowThis trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New mRNA vaccine aims to stop ovarian Cancer's return
Disease control Recruiting nowThis early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…
Phase: PHASE1 • Sponsor: Epitopea Ltd • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Immune cells retrained to hunt ovarian cancer in new trial
Disease control Recruiting nowThis phase 1 trial investigates a new treatment for advanced ovarian cancer that has stopped responding to platinum chemotherapy. The therapy uses a patient's own immune cells, called T cells, which are genetically modified in a lab to recognize and attack a protein called TAG72 …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug SIM0505 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…
Phase: PHASE1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Immunotherapy plus chemo shows promise for rare cervical cancer
Disease control Recruiting nowThis study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy and radiation can help women with a rare and aggressive type of cervical cancer called small cell neuroendocrine carcinoma. About 45 women with early to advanced stages of the disease…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New hope for recurrent endometrial cancer: Rina-S faces off against standard chemo
Disease control Recruiting nowThis study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after platinum-based chemo and immunotherapy. About 660 participants will be randomly assigned to receive either Rina-…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug SHR-4610 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Immunotherapy duo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with MET gene change
Disease control Recruiting nowThis phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Recruiting nowThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase: PHASE2 • Sponsor: Val Adams • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to boost immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill shows promise in early cancer trial
Disease control Recruiting nowThis early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced cervical cancer: adding immunotherapy before standard care
Disease control Recruiting nowThis phase III trial tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 336 participants will be rando…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug CS5007 targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …
Phase: PHASE1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on advanced cancers in first human test
Disease control Recruiting nowThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase: PHASE1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Targeted therapy boost for aggressive uterine cancer under study
Disease control Recruiting nowThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug MRG007 enters early human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo targets tough ovarian cancers
Disease control Recruiting nowThis early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo aims to shrink HER2-Positive tumors
Disease control Recruiting nowThis study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive solid tumors (excluding breast cancer). Both drugs block signals that help cancer cells grow. The trial enrolls 70 adults with advanced or recurrent gynecologi…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug targets cancer DNA in advanced tumors
Disease control Recruiting nowThis early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New Dual-Antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Ottimo Pharma Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for advanced cancer: first human trial of GS-0201 begins
Disease control Recruiting nowThis early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called LBL-024 combined with the chemotherapy paclitaxel in people with ovarian cancer that has become resistant to platinum-based treatments. The trial involves 110 participants and aims to see if the combination can shrink tumors and delay disease pr…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail shows promise for recurrent ovarian and endometrial cancers
Disease control Recruiting nowThis study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people with ovarian or endometrial cancer that has come back but still responds to platinum-based treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 5…
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug BNT3214 enters human trials for advanced tumors
Disease control Recruiting nowThis study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New liposomal drug takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…
Phase: PHASE1, PHASE2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for advanced cancer: first human trial of FP008 begins
Disease control Recruiting nowThis early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…
Phase: PHASE1 • Sponsor: Zhuhai Fapon Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cancer drug SHR-4298 enters early human testing
Disease control Recruiting nowThis study is testing an experimental drug called SHR-4298 in 200 people with advanced solid tumors that cannot be removed by surgery or cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow cancer…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: experimental drug ubamatamab enters phase 2 trials
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug COM503 enters first human trial for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug azenosertib takes on Chemo-Resistant ovarian cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…
Phase: PHASE3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
Disease control Recruiting nowThis trial is investigating whether adding radiation therapy to a standard combination of chemotherapy and two targeted drugs can improve outcomes for people with stage IVB cervical cancer. The study combines external beam radiation and internal brachytherapy with cisplatin, pacl…
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase: PHASE1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for advanced tumors? first human trial of DS-3939a begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase: PHASE1, PHASE2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug cocktail aims to outsmart aggressive uterine cancer
Disease control Recruiting nowThis phase 3 trial is testing whether a targeted drug (trastuzumab deruxtecan) combined with immunotherapy (rilvegostomig or pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced or recurrent endometrial cancer that has a specific prot…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted drug boost standard ovarian cancer therapy?
Disease control Recruiting nowThis trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could less be more? new trial tailors endometrial cancer treatment to tumor type
Disease control Recruiting nowThis phase II study is testing whether women with certain types of early-stage endometrial cancer can safely receive less aggressive treatment after surgery. The approach is guided by the tumor's molecular profile—either POLE-mutated or p53 wildtype/NSMP. Around 393 participants …
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug MGC026 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Roche offers lifeline: continued cancer drug access for trial patients
Disease control Recruiting nowThis study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug BGB-B455 targets tough tumors in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental injection targets tumors directly in new cancer trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…
Phase: PHASE1 • Sponsor: Vaxiion Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
MRNA cancer shots: new hope or hype?
Disease control Recruiting nowThis early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug tackle Hard-to-Treat gynecologic cancers?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can immunotherapy plus hormones spare the womb in early endometrial cancer?
Disease control Recruiting nowThis trial is investigating whether combining an immunotherapy drug (a PD-1 inhibitor like sintilimab or pembrolizumab) with progesterone therapy can help young women with early-stage, mismatch repair-deficient (MMRd) endometrial cancer achieve complete remission while preserving…
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug DS1025a takes on advanced solid tumors in first human trial
Disease control Recruiting nowThis trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for tough endometrial cancer: Four-Drug combo trial launches
Disease control Recruiting nowThis Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cancer drug MBS8(1V270) enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…
Phase: PHASE1 • Sponsor: MonTa Biosciences ApS • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat breast cancers
Disease control Recruiting nowThis early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a simple asthma drug prevent a dangerous immunotherapy side effect?
Disease control Recruiting nowThis study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Phase: PHASE1, PHASE2 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can robotic surgery match open surgery in beating cervical cancer?
Disease control Recruiting nowThis trial asks whether robot-assisted hysterectomy is as effective as traditional open surgery for treating early-stage cervical cancer. About 800 women with stage IB (excluding IB3) or IIA1 cervical cancer will be randomly assigned to one of the two surgical approaches. The mai…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New master trial aims to speed up cancer treatments for kids
Disease control Recruiting nowThis trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Shorter maintenance therapy may be just as effective for BRCA-Linked ovarian cancer
Disease control Recruiting nowThis phase 3 trial tests whether taking the drug olaparib for one year works as well as taking it for two years to keep ovarian cancer from coming back. The study includes 880 people with advanced ovarian cancer (stage III or IV) who have a BRCA mutation or similar DNA repair pro…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Custom-Made immune cell vaccine turn the tide against solid tumors?
Disease control Recruiting nowThis trial tests a personalized approach to treating advanced solid tumors. Doctors take a patient's own immune cells, train them to recognize that patient's specific cancer mutations, and inject them back under the skin. The goal is to see if these customized cells can safely tr…
Phase: NA • Sponsor: ZSky Biotech Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New Triple-Drug attack on cervical cancer enters final testing
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Exercise as medicine: tailored workouts may rebuild strength after cancer
Disease control Recruiting nowThis trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…
Phase: NA • Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug STRO-004 takes on advanced cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Hope for Platinum-Resistant ovarian cancer: new pill takes on chemo
Disease control Recruiting nowThis Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for ovarian cancer: phase 3 trial tests targeted drug against Tough-to-Treat tumors
Disease control Recruiting nowThis large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New vaccine aims to halt ovarian cancer recurrence detected in blood
Disease control Recruiting nowThis phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug HWK-016 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for hard-to-treat ovarian cancer: experimental drug targets key protein
Disease control Recruiting nowThis study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for cancer patients: experimental drug aims to stop dangerous blood clots
Disease control Recruiting nowThis study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowThis trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…
Phase: PHASE1, PHASE2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo trial targets Hard-to-Treat breast and ovarian cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called AZD8421, alone or with other cancer drugs, in people with advanced ER+ breast cancer or high-grade ovarian cancer. The study aims to find safe doses and see if the drug can shrink tumors. About 564 women aged 18 and older will t…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug targets 13 cancers in major trial
Disease control Recruiting nowThis study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Zinc-Based compound fight cancer?
Disease control Recruiting nowThis trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…
Phase: PHASE1, PHASE2 • Sponsor: Vector Vitale LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for womb cancer: drug duo aims to slow tumor growth
Disease control Recruiting nowThis study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug hopes to shrink tumors in patients out of options
Disease control Recruiting nowThis study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug HWK-007 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New study targets ovarian cancer in black women: could genes affect treatment?
Disease control Recruiting nowThis study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take nirapa…
Phase: PHASE4 • Sponsor: University of Miami • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a condensed radiation course after cervical cancer surgery be just as safe and effective?
Disease control Recruiting nowThis trial is testing a shorter course of radiation therapy for women who have had surgery for cervical cancer. Instead of the usual many weeks of daily treatments, participants receive a slightly higher dose each day over about three and a half weeks. The goal is to see if this …
Phase: NA • Sponsor: Manni Huang • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new immunotherapy combo shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for ovarian cancer: Rina-S faces off against chemo in major trial
Disease control Recruiting nowThis large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced cancer?
Disease control Recruiting nowThis trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could your own tumor cells fight your cancer? early trial begins
Disease control Recruiting nowThis early-phase trial tests a personalized therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a sample of the patient's tumor, grow them into large numbers in a lab, and infuse them back into the patient. …
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Cancer-Killing virus trial launches for patients out of options
Disease control Recruiting nowThis Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…
Phase: PHASE1 • Sponsor: ViroMissile, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug Rina-S shows promise in battling Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New gene therapy combo aims to boost ovarian cancer survival
Disease control Recruiting nowThis phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…
Phase: PHASE3 • Sponsor: Imunon • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to boost immune system against advanced cancers
Disease control Recruiting nowThis study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to wipe out hidden ovarian cancer cells
Disease control Recruiting nowThis study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…
Phase: PHASE1, PHASE2 • Sponsor: Imunon • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for ovarian cancer: targeted drug combo enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill targets HER2 cancers in phase 2 trial
Disease control Recruiting nowThis study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Weekly chemo boost could help ovarian cancer patients who Don't respond to standard treatment
Disease control Recruiting nowThis phase 3 trial tests whether a denser weekly chemotherapy schedule (carboplatin every 3 weeks plus weekly paclitaxel) can help ovarian cancer patients whose tumors are not responding well to standard treatment. The study enrolls 250 adults with advanced ovarian cancer who hav…
Phase: PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…
Phase: PHASE1, PHASE2 • Sponsor: Everest Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for tumors that beat immunotherapy? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…
Phase: PHASE1 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo plus radiation targets tough uterine cancer
Disease control Recruiting nowThis early-stage trial is testing whether combining two cancer drugs (lenvatinib and pembrolizumab) with a shorter course of pelvic radiation is safe for people with recurrent or unresectable endometrial cancer. The study aims to find the best dose of lenvatinib when used in this…
Phase: PHASE1 • Sponsor: Aaron Wolfson • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Tailor-Made vaccine aims to train immune system against cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo targets hard-to-treat cancers with KRAS mutation
Disease control Recruiting nowThis study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a pill boost the immune system to fight Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called OATD-02 in people with advanced or metastatic colorectal, ovarian, pancreatic, or renal cell cancer. The goal is to see if the drug is safe and whether it can help the immune system attack tumors by increasing arg…
Phase: PHASE1 • Sponsor: Molecure S.A. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A simple drain may slash wound infections after gynecologic cancer surgery
Disease control Recruiting nowThis trial tests whether placing a small closed-suction drain under the skin before closing the incision can reduce wound complications in women with thick subcutaneous tissue (2.5 cm or more) undergoing midline abdominal surgery for gynecologic cancer. Half of the participants w…
Phase: NA • Sponsor: Mahmut Yassa • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.
Phase: PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Robot or scalpel? a Head-to-Head trial for cervical cancer surgery
Disease control Recruiting nowThis trial compares two surgical approaches for early-stage cervical cancer: robotic-assisted surgery using the da Vinci system versus traditional open surgery. Researchers are asking whether the minimally invasive robotic method can match or improve upon open surgery in terms of…
Phase: NA • Sponsor: GOG Foundation • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…
Phase: PHASE1, PHASE2 • Sponsor: PharmaMar • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a new targeted pill tame advanced cancers? a phase i trial seeks answers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called TQB3107, taken as a tablet, in people with advanced malignant tumors. The goal is to find a safe dose and understand how the body processes the drug. TQB3107 is designed to block a specific target inside cancer cells, poten…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can heated chemo during surgery help older women with ovarian cancer?
Disease control Recruiting nowThis study tests whether giving heated chemotherapy directly into the abdomen during surgery is safe for women aged 70 and older with advanced ovarian cancer. The treatment, called NIPEC with carboplatin, is delivered at normal body temperature for 90 minutes right after the surg…
Phase: PHASE1 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug called ROSE12 help fight advanced solid tumors?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a triple-threat approach wipe out cervical cancer before surgery?
Disease control Recruiting nowThis phase II trial is testing whether a short course of radiation combined with the immunotherapy drug adebrelimab and a single platinum chemotherapy drug can eliminate all signs of cancer before surgery in women with locally advanced cervical cancer. Participants receive the co…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors? a trial aims to find out
Disease control Recruiting nowThis phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
A new care pathway aims to get cancer surgery patients home safer and faster
Disease control Recruiting nowThis large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…
Phase: NA • Sponsor: Regional Specialist Hospital in Wroclaw • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could an AI-Designed pill take on Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new antibody help the immune system fight advanced cancers?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…
Phase: PHASE1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…
Phase: PHASE1, PHASE2 • Sponsor: Alyssum Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…
Phase: PHASE1 • Sponsor: Duboce Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called APG-2449 in people with advanced solid tumors, including certain lung cancers, mesothelioma, esophageal cancer, and ovarian cancer. APG-2449 is designed to block several proteins (FAK, ALK, and ROS1) that help can…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Experimental pill takes on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Exercise and diet counseling may help cancer patients finish chemo
Disease control Recruiting nowThis study tests whether a program of exercise and nutrition counseling helps women with ovarian or endometrial cancer stick with their chemotherapy plan. About 200 women who are about to start chemotherapy will be randomly assigned to either receive weekly coaching sessions on p…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Targeted pill aims to halt recurrent ovarian and endometrial cancers
Disease control Recruiting nowThis phase II trial tests the drug abemaciclib in people whose ovarian or endometrial cancer has returned and whose tumors have a specific genetic change (CDK4/6 pathway activation). Abemaciclib is a pill that blocks certain enzymes that cancer cells need to grow. The study will …
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple diet replace an enema before endometrial cancer surgery?
Disease control Recruiting nowThis trial tests whether a 3-day low-residue diet can replace a rectal enema for bowel preparation before laparoscopic endometrial cancer surgery. One hundred women scheduled for surgery will be randomly assigned to either the diet or an enema. The study measures how well the sur…
Phase: NA • Sponsor: Mahmut Yassa • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
Disease control Recruiting nowThis trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Food aid may boost cancer treatment completion in food-insecure patients
Disease control Recruiting nowThis study looks at whether providing food assistance—like food boxes and produce vouchers—helps cancer patients who struggle with food insecurity stay on track with their treatment. Researchers will compare patients who receive six months of food support to those who get standar…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental shot aims to rev up immune system against advanced cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…
Phase: PHASE1 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental drug PA5 targets arginine to starve advanced cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Particle beam and immune therapy join forces against cervical cancer
Disease control Recruiting nowThis study investigates a new treatment approach for locally advanced cervical cancer that combines carbon ion radiotherapy with immunotherapy (anti-PD-1) and chemotherapy. The goal is to see if this triple therapy improves how long patients live without their cancer progressing.…
Phase: NA • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase: PHASE2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
Disease control Recruiting nowThis phase 2 trial investigates whether adding stereotactic body radiotherapy (SBRT) to the PARP inhibitor niraparib can improve control of ovarian cancer that has spread to a limited number of new spots after prior PARP inhibitor therapy. Participants will receive SBRT alone or …
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Tiny radioactive seeds may offer new hope for women with recurrent pelvic cancer
Disease control Recruiting nowThis study tests a radiation treatment called Cesium-131 brachytherapy for women whose cervical or endometrial cancer has returned in the vagina after prior pelvic radiation. Tiny radioactive seeds are placed directly into the tumor to kill cancer cells while sparing healthy orga…
Phase: NA • Sponsor: Denise Fabian • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Immune-Engaging drug takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage trial tests an investigational drug called NTB-928 in women with ovarian cancer that has come back or no longer responds to standard treatments. NTB-928 is designed to direct the body's immune T cells to attack cancer cells by targeting a protein called FRα. The …
Phase: PHASE1 • Sponsor: TeneoSeven, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Tailored rehab program aims to help young adults reclaim life after cancer
Disease control Recruiting nowThis trial tests a 16-week rehabilitation program called YATAC, designed specifically for young adults aged 18–39 who have or have had cancer. The program includes physical activity, mental health support, nutrition advice, and help with education or work. Researchers want to see…
Phase: NA • Sponsor: University of Aarhus • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Exercise after cancer: could resistance training rebuild bodies?
Disease control Recruiting nowThis study tests whether a closely supervised resistance training program can improve functional mobility, body composition, and strength in people who have been treated for cancer. Participants aged 20 to 89 will follow a structured exercise regimen during or after their cancer …
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug JS212 aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called JS212 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then expanding to see if the drug can shrink tumors. Researchers will monitor side effects and measu…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo aims to outsmart recurrent ovarian cancer
Disease control Recruiting nowThis trial tests a new experimental drug called CPI-0209 (Tulmimetostat) combined with the chemotherapy drug carboplatin in women whose ovarian cancer has returned but still responds to platinum-based treatments. The study aims to find the safest dose of CPI-0209 when given with …
Phase: PHASE1 • Sponsor: Lan Coffman • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase: PHASE1, PHASE2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a simple chat with your pharmacist boost cancer pill adherence?
Disease control Recruiting nowThis study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients eac…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…
Phase: NA • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Radiation that adapts daily: a smarter way to hit tumors and spare organs
Disease control Recruiting nowThis trial tests a new radiation technique for people with abdominal or pelvic tumors. Standard radiation gives the same dose each session, but this approach adjusts the dose daily based on the exact position of the tumor and nearby organs. The goal is to deliver more radiation t…
Phase: NA • Sponsor: University of Zurich • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
Disease control Recruiting nowThis early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that ha…
Phase: EARLY_PHASE1 • Sponsor: Celest Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a tailored quit-smoking program help cancer patients and survivors kick the habit for good?
Disease control Recruiting nowThis study explores how to best help cancer patients, survivors, and their caregivers quit tobacco. Participants can choose between group or one-on-one counseling sessions. The goal is to see if this program is practical and well-received, paving the way for better tobacco cessat…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a mesh shield ovarian cancer patients from painful hernias?
Disease control Recruiting nowThis trial tests whether placing a surgical mesh during abdominal closure can prevent incisional hernias in women undergoing ovarian cancer surgery. It also examines if a negative pressure wound dressing reduces infection risk. Participants are randomly assigned to one of four gr…
Phase: NA • Sponsor: Hospital Vall d'Hebron • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a common heart drug boost ovarian cancer treatment?
Disease control Recruiting nowThis phase 2 trial tests whether adding propranolol, a widely used beta-blocker, to standard chemotherapy before surgery can improve outcomes for women with advanced high-grade serous ovarian cancer. Participants receive propranolol pills alongside paclitaxel and carboplatin, fol…
Phase: PHASE2 • Sponsor: Bai-Rong Xia • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can cervical cancer patients stop immunotherapy early? new study investigates
Disease control Recruiting nowThis study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others conti…
Phase: PHASE4 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Own stem cells may shield bone marrow during ovarian cancer chemo
Disease control Recruiting nowThis trial investigates whether giving back a patient's own blood stem cells after chemotherapy can help their bone marrow recover faster. The study includes women aged 18–60 with recurrent or metastatic ovarian cancer who are scheduled for chemotherapy. The goal is to reduce sev…
Phase: NA • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could storing your own stem cells shield bone marrow during cancer treatment?
Disease control Recruiting nowThis trial investigates whether collecting and storing a patient's own blood stem cells before chemoradiotherapy, then re-infusing them after treatment, can help rebuild healthy blood cells faster. The study includes 40 women with cervical cancer who are scheduled for chemoradiot…
Phase: NA • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug aimed at folate receptor shows promise for tough endometrial cancer
Disease control Recruiting nowThis phase 2 trial tests a drug called mirvetuximab soravtansine in 50 women with a specific type of endometrial cancer that has come back or won't go away. The drug targets a protein called folate receptor alpha, which is often found on these cancer cells. Researchers want to se…
Phase: PHASE2 • Sponsor: Alessandro Santin • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase: PHASE2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Triple-Drug cocktail aims to boost ovarian cancer surgery success
Disease control Recruiting nowThis phase 2 trial is testing a combination of three drugs—ipalotinib, sunitinib, and olaparib—given before surgery to people with a specific type of advanced ovarian cancer (HRD-positive). The goal is to shrink tumors enough to allow complete removal during surgery. The study wi…
Phase: PHASE2 • Sponsor: Bai-Rong Xia • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on Hard-to-Treat cervical cancer
Disease control Recruiting nowThis study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and rese…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase: PHASE1, PHASE2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune cells take on ovarian cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing whether specially engineered immune cells (OC-CTLs) can safely fight ovarian cancer. Twenty women with advanced-stage disease will receive 2 to 4 infusions of these cells. Researchers will monitor side effects and check if tumors shrink or stabil…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat cervical cancer
Disease control Recruiting nowThis trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to outsmart resistant uterine cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining hormone therapy (letrozole) with a targeted drug (abemaciclib), and possibly adding metformin or gedatolisib, can control estrogen-receptor-positive endometrial cancer that has returned or spread. The study enrolls adults with this cance…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a coordinated care program boost quality of life for cancer patients facing social hardships?
Disease control Recruiting nowThis study tests a program called Comprehensive Connected Cancer Care (C4) for people newly diagnosed with cancer who also have social needs (like trouble paying for medicine or getting to appointments). The program uses patient navigators, a digital needs assessment, and better …
Phase: NA • Sponsor: Timothy Mullett • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Two-Drug combo targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…
Phase: PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug H1710 enters first human tests
Disease control Recruiting nowThis early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …
Phase: PHASE1 • Sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…
Phase: PHASE2 • Sponsor: Ira Winer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could injecting immunotherapy into lymph nodes boost cervical cancer treatment?
Disease control Recruiting nowThis early-stage trial explores whether injecting the immunotherapy drug nivolumab directly into lymph nodes before standard surgery is feasible and safe for people with cervical cancer. The study involves 12 participants and aims to see if this targeted approach can shrink tumor…
Phase: PHASE1 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Fighting viruses take on advanced tumors in early trial
Disease control Recruiting nowThis phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a 3-Week radiation course beat the standard 5-Week for cervical cancer?
Disease control Recruiting nowThis study tests whether a shorter, 3-week course of radiation works as well as the standard 5-week course for women with locally advanced cervical cancer. About 396 women will be randomly assigned to one of the two schedules, both combined with chemotherapy. If the shorter sched…
Phase: NA • Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug OVV-01 injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…
Phase: PHASE1 • Sponsor: Joint Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could your own immune cells fight ovarian cancer? tiny trial aims to find out
Disease control Recruiting nowThis early-stage trial is testing whether a patient's own tumor-fighting immune cells (called TILs) can be safely used to treat recurrent ovarian cancer. Researchers take a sample of the tumor, grow the immune cells in a lab, and then inject them back into the patient. Only 6 peo…
Phase: NA • Sponsor: Yong Wha Moon • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could 3 radiation doses beat 4 for cervical cancer?
Disease control Recruiting nowThis study compares a shorter course of brachytherapy (3 sessions) to the standard 4-session regimen for locally advanced cervical cancer. About 41 participants will receive either 3 or 4 high-dose radiation treatments based on what is feasible for them. The goal is to see if the…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug YH32364 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Cancer drug pelabresib gets Long-Term safety check in extension trial
Disease control Recruiting nowThis study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental cell therapy targets multiple cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…
Phase: PHASE1 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug AN8025 tested in patients with advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New radiation method targets tough tumors
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…
Phase: PHASE2 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Dual immunotherapy plus chemo may shrink cervical tumors before surgery
Disease control Recruiting nowThis phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery in 103 women with locally advanced cervical cancer. The goal is to see if this approach can shrink tumors enough to allow less extensive…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets Hard-to-Treat cancers with a specific gene mutation
Disease control Recruiting nowThis study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New test could spare women unnecessary biopsies for uterine cancer
Diagnosis Recruiting nowThis study is working on a new, non-invasive test to help rule out uterine cancer in women aged 45 and older who have abnormal bleeding. Researchers will collect samples from 4,500 women to see how well the test detects cancer and identifies benign cases. If successful, it could …
Sponsor: PinkDx, Inc. • Aim: Diagnosis
Last updated Aug 18, 2026 02:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can AI spot ovarian cancer on CT scans before It's too late?
Diagnosis Recruiting nowThis study is testing whether an artificial intelligence (AI) tool called CAT-OV can accurately identify ovarian cancer on CT scans. Ovarian cancer is often found late, when it's harder to treat, and current screening methods aren't reliable enough. The AI is being trained and te…
Sponsor: Chang Gung Memorial Hospital • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new PET tracer light up hidden cancers?
Diagnosis Recruiting nowThis trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…
Phase: NA • Sponsor: Peking University Third Hospital • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
At-Home HPV test could boost screening in underserved women
Diagnosis Recruiting nowThis study explores whether women can accurately collect their own samples for HPV testing, which could make cervical cancer screening easier and more accessible. The research focuses on minority women who are often under-screened, using community health workers to help with the …
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
Can a new PET tracer reveal a key cancer target?
Diagnosis Recruiting nowThis trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New devices could revolutionize cervical cancer screening in africa
Diagnosis Recruiting nowThis study in Mozambique is testing two new technologies to improve cervical cancer screening and diagnosis. Researchers will compare a rapid HPV test and a special imaging device against standard methods in about 678 women. The goal is to find faster, more accurate ways to detec…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New imaging tracer could spot tumors more clearly
Diagnosis Recruiting nowThis early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
New blood test could spot cancer early – 6,000+ join study
Diagnosis Recruiting nowThis study tests a new blood and urine test that looks for DNA markers to detect cancer early and identify where it started. Researchers at Mayo Clinic will enroll about 6,150 people, including those with and without cancer. The goal is to see if these tests can accurately find c…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
Swab test could spot hidden uterine cancer early
Diagnosis Recruiting nowThis study is collecting vaginal fluid samples from 4,200 people to develop a new test for endometrial cancer. Participants include those with abnormal uterine bleeding or a recent endometrial cancer diagnosis. The goal is to find biomarkers that could lead to a simple, non-invas…
Sponsor: Exact Sciences Corporation • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
New Low-Cost HPV test could save lives in poor countries
Diagnosis Recruiting nowThis study tests a low-cost HPV test that can be done in one visit, so women get results and treatment on the same day. It aims to reduce the number of women lost to follow-up in cervical cancer screening programs. The study will enroll 1,000 women in remote areas of El Salvador.
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowThis study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Could a simple estrogen treatment sharpen the view for cervical cancer screening?
Diagnosis Recruiting nowThis trial tests whether applying vaginal estrogen before a colposcopy helps doctors see the cervix more clearly in women aged 50 and older. As women age, the area where precancerous changes occur can become harder to view, which may lead to missed diagnoses or repeat procedures.…
Phase: NA • Sponsor: University of Aarhus • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Can a tracer that hunts unstable iron light up hidden tumors?
Diagnosis Recruiting nowThis phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…
Phase: PHASE1 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New imaging agent could sharpen cancer detection
Diagnosis Recruiting nowThis trial evaluates a radioactive tracer called 68Ga-DOTA/NOTA-FAPI-04, given as a single injection before a PET/CT scan, to see if it can better identify primary tumors and metastases in people with various cancers. Researchers will measure how strongly the tracer accumulates i…
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jul 23, 2026 00:00 UTC
-
Could a simple blood test replace invasive tissue biopsies for cancer genetics?
Diagnosis Recruiting nowThis study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid …
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New PET tracer aims to spot hidden cancer spread in the abdomen
Diagnosis Recruiting nowThis phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …
Phase: PHASE2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Simple blood test aims to spot multiple cancers early
Diagnosis Recruiting nowThis study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New PET tracer targets cancer cells for sharper tumor imaging
Diagnosis Recruiting nowThis study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…
Phase: PHASE1, PHASE2 • Sponsor: Heron Neutron Medical Corp. • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
HPV DNA test could slash cervical cancer deaths in High-Risk populations
Diagnosis Recruiting nowThis study evaluates whether an HPV DNA test can more accurately detect pre-cancerous cervical changes than standard Pap smears in 1,500 women in South Africa, including those with and without HIV. Participants undergo HPV testing, followed by colposcopy and biopsy if needed. The…
Sponsor: University of Pretoria • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
Could a simple urine test replace the pap smear for cervical cancer screening?
Diagnosis Recruiting nowThis study investigates whether urine samples can be used to screen for cervical cancer in women living with HIV. Researchers will compare the accuracy of urine HPV testing with self-collected and provider-collected samples to detect cervical precancer (CIN2 or worse). The goal i…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New scan technique could sharpen tumor targeting during radiation
Diagnosis Recruiting nowThis study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
AI reads ultrasound to spot hidden uterine cancer
Diagnosis Recruiting nowThis study explores whether an artificial intelligence (AI) program can accurately identify endometrial cancer or precancerous changes by analyzing standard transvaginal ultrasound images. Researchers will compare the AI's predictions with results from endometrial biopsies in 300…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New decision aid could boost use of IUDs for cancer prevention
Prevention Recruiting nowThis study aims to create an educational tool that helps women and their doctors make informed choices about using a levonorgestrel-releasing intrauterine system (LNG-IUS) to prevent endometrial cancer. Researchers will survey 270 women, both with and without a history of the dis…
Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New program aims to boost cervical cancer screening in high-risk women
Prevention Recruiting nowThis study tests a program called PINPOINT that helps women with obesity or diabetes get screened for cervical cancer. About 20 women who are behind on screening will be offered options like self-collection or a Pap smear. The goal is to see if the program is practical and well-l…
Phase: NA • Sponsor: University of Florida • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
Could a less drastic surgery prevent ovarian cancer in High-Risk women?
Prevention Recruiting nowThis study looks at two surgeries to reduce ovarian cancer risk in women with BRCA1 gene changes. One surgery removes only the fallopian tubes, while the other removes both tubes and ovaries. Researchers want to see if removing just the tubes works nearly as well at preventing ca…
Phase: NA • Sponsor: NRG Oncology • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
A genetic score could sharpen breast cancer risk prediction
Prevention Recruiting nowThis study tests whether adding a polygenic risk score (PRS) — a measure based on 313 genetic markers — to the standard CanRisk model can improve breast cancer risk prediction and prevention. About 100 women at increased risk will receive genetic counseling, a blood draw, and the…
Phase: NA • Sponsor: Catholic University of the Sacred Heart • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
At-Home HPV tests could boost cervical cancer screening in border communities
Prevention Recruiting nowThis study tests whether at-home HPV self-sampling (using urine or a vaginal swab) can help more people get screened for cervical cancer compared to the traditional in-clinic Pap smear. About 735 Latinx individuals aged 30-65 who haven't had a Pap test in at least three years wil…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New study aims to ease cancer journey for LGBTQ+ patients and loved ones
Symptom relief Recruiting nowThis study is testing a program called FOCUS ON US, designed to help sexual and gender minority (LGBTQ+) cancer patients and their caregivers. The program includes five sessions covering topics like family involvement, coping skills, and symptom management. Researchers want to se…
Phase: NA • Sponsor: Charles Kamen • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
New study monitors eye health in cervical cancer drug TIVDAK
Symptom relief Recruiting nowThis study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
Could a simple activity-based therapy lift depression in older cancer survivors?
Symptom relief Recruiting nowThis study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
Acupuncture may restore periods lost to chemo in young cancer survivors
Symptom relief Recruiting nowThis study looks at whether acupuncture can help young women (ages 15-40) with cancer get their periods back after chemotherapy caused them to stop. About 60 participants will receive acupuncture or usual care. Researchers will measure how many people join and finish the study, a…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
A good Night's sleep: could a simple program ease Cancer's toll on rest?
Symptom relief Recruiting nowThis study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Acupuncture and ear seeds may help cancer patients need less pain medication
Symptom relief Recruiting nowThis study tests whether adding electroacupuncture and ear acupoint pressing beans to a standard opioid painkiller can better relieve severe cancer pain that doesn't respond to usual treatments. About 30 adults with refractory cancer pain will receive the combination for two week…
Phase: EARLY_PHASE1 • Sponsor: Qinghai Red Cross Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can a personalized exercise program boost recovery in cancer survivors?
Symptom relief Recruiting nowThis pilot trial tests whether a supervised exercise program is safe, helpful, and practical for adults who have had breast or gynecologic cancer. Participants will take part in a 12-week program combining strength and aerobic training under trained guidance. The study focuses on…
Phase: NA • Sponsor: Jess S. Gorzelitz • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Writing away the worry: new study tests expressive writing for cancer survivors
Symptom relief Recruiting nowThis study tests whether expressive writing—reading and writing about positive experiences—can help cancer survivors manage stress. About 414 survivors will participate from home using a computer or smartphone. The goal is to see if this simple activity can lower stress and impro…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Meditation may ease depression in advanced cancer patients and caregivers
Symptom relief Recruiting nowThis study tests two supportive care programs—meditation and discussion sessions—for people with advanced (stage IV) cancer and their family caregivers. Researchers want to see if these programs can reduce depressive symptoms and improve quality of life. About 400 patient-caregiv…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can a smart digital program restore sleep for cancer survivors?
Symptom relief Recruiting nowThis pilot trial tests an adaptive stepped-care digital intervention to improve sleep in Chinese cancer survivors with mild-to-moderate insomnia. Participants first receive a self-guided web-based CBT-I program or a simple exercise program; those who don't improve may be stepped …
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New support program hopes to ease Cancer's toll on chinese patients
Symptom relief Recruiting nowThis study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New telehealth program aims to ease depression and fatigue in latino cancer patients
Symptom relief Recruiting nowThis study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Magic mushroom therapy could help cancer survivors beat depression
Symptom relief Recruiting nowThis study tests whether psilocybin, the active ingredient in magic mushrooms, combined with talk therapy can safely help cancer survivors with depression or anxiety. Twenty adults who have finished cancer treatment and have no brain involvement will receive a single dose of psil…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New program aims to ease burden on caregivers of cancer and diabetes patients
Symptom relief Recruiting nowThis study tests a program called enCompass Humana, which provides coaching and resources to unpaid caregivers of adults with both cancer and diabetes. The goal is to see if the program is practical and helpful for caregivers, improving their coping skills and reducing loneliness…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to reduce radiation side effects for women with gynecologic cancers
Symptom relief Recruiting nowThis study compares two standard radiation methods—proton therapy and photon therapy—for women with newly diagnosed cervical or endometrial cancer. The goal is to see which approach causes fewer stomach and bowel side effects. About 116 participants will be randomly assigned to o…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Free food and online cooking classes could help cancer survivors thrive
Symptom relief Recruiting nowThis study looks at whether giving cancer survivors free healthy food and online cooking lessons can improve their health and well-being. The program is for survivors who struggle to afford food and are treated at a safety-net hospital. Researchers will check if the program is sa…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
New program aims to ease cancer Patients' pain and depression
Symptom relief Recruiting nowThis study tests a program called CARES that provides cancer patients with integrated screening and stepped care for symptoms like pain and depression. About 1,750 adults with cancer will be randomly assigned to CARES or standard care. The goal is to see if CARES improves quality…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Digital therapy aims to tame the fear that haunts cancer survivors
Symptom relief Recruiting nowThis trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Dance your way to better sleep: latin moves tested in cancer survivors
Symptom relief Recruiting nowThis study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Guarana: a natural energy boost for cancer fatigue?
Symptom relief Recruiting nowThis phase 2 trial tests whether guarana, a natural supplement from the Amazon, can reduce fatigue in 86 people with neuroendocrine tumors or gynecologic cancers. Participants take either guarana or a placebo daily for up to 42 days, and researchers measure changes in fatigue usi…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New study aims to reduce leg swelling in endometrial cancer surgery
Symptom relief Recruiting nowThis study tests whether a less invasive lymph node procedure (sentinel mapping) can lower the risk of long-term leg swelling compared to standard lymph node removal. About 428 women with stage I endometrial cancer will be followed for 18 months after hysterectomy. The goal is to…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Could fasting boost chemo outcomes? small trial tests the idea in ovarian cancer
Symptom relief Recruiting nowThis study looks at whether intermittent fasting (not eating for 16 hours a day, 5 days a week) is safe and doable for people with advanced ovarian cancer who are getting chemotherapy before surgery. Twenty participants will either follow the fasting schedule or standard diet adv…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New pill aims to stop chemo sickness in its tracks
Symptom relief Recruiting nowThis study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New shot aims to ease depression and anxiety in cancer and chronic disease patients
Symptom relief Recruiting nowThis study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…
Phase: PHASE2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New program aims to cut hospital visits by helping cancer patients speak up
Symptom relief Recruiting nowThis trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
A hug in a blanket: could deep pressure calm cancer infusion anxiety?
Symptom relief Recruiting nowThis trial tests whether using a weighted blanket during a first cancer infusion (like chemotherapy) can lower anxiety and distress compared to a regular blanket. The idea is that the deep touch pressure from the blanket may calm the nervous system and increase feelings of well-b…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Magic mushroom compound tested for cancer pain that opioids Can't touch
Symptom relief Recruiting nowThis study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…
Phase: PHASE2 • Sponsor: Yvan Beaussant, MD, MSci • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
New trial aims to ease cancer Patients' breathlessness with tailored oxygen and relaxation techniques
Symptom relief Recruiting nowThis study tests a personalized program called SPOT-ON for cancer patients suffering from severe shortness of breath. Participants will receive a combination of breathing techniques, relaxation methods, posture adjustments, and oxygen-based therapies, either starting early or aft…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a Culturally-Tailored therapy reduce anxiety in advanced cancer patients?
Symptom relief Recruiting nowThis study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Can a smartphone app teach resilience to young cancer patients?
Symptom relief Recruiting nowThis pilot trial tests whether a mobile app version of a resilience-building program, called mPRISM, is acceptable and helpful for adolescents and young adults recently diagnosed with cancer. The app teaches coping skills like stress management, goal-setting, and reframing negati…
Phase: NA • Sponsor: Seattle Children's Hospital • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Massage during chemo: a new way to ease cancer treatment stress?
Symptom relief Recruiting nowThis small study will test whether giving a 15-20 minute massage during infusion therapy can reduce pain and anxiety in women with gynecologic cancer. Twenty-four participants will be randomly assigned to receive either a hand, foot, or neck/shoulder massage or simply talk with t…
Phase: NA • Sponsor: Jill Cole • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Exercise coaching may ease fatigue during radiation for endometrial cancer
Symptom relief Recruiting nowThis study tests whether a personalized activity coaching program can help women feel less tired during pelvic radiation therapy for endometrial cancer. Sixteen participants will be randomly assigned to receive coaching or usual care. The main goal is to see if the program is pra…
Phase: NA • Sponsor: Inova Health Care Services • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Mushroom extract put to the test for advanced cancer Well-Being
Symptom relief Recruiting nowThis trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could palliative care ease the burden of childhood cancer trials?
Symptom relief Recruiting nowThis study looks at whether adding pediatric palliative care consultations can improve quality of life for children with cancer and their families while they take part in early-phase (phase 1) clinical trials. Phase 1 trials test new drugs for safety, but they can cause side effe…
Phase: EARLY_PHASE1 • Sponsor: Phoenix Children's Hospital • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Digital brain training may ease 'chemo brain' — a trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether two types of home-based digital cognitive training can help cancer survivors who have memory, attention, or thinking problems after chemotherapy. Participants will use either a computer program (BrainHQ) or a virtual reality cognitive training for 10 week…
Phase: NA • Sponsor: Biogipuzkoa Health Research Institute • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
A single sheet of paper may transform how doctors deliver cancer news
Symptom relief Recruiting nowThis trial tests whether a one-page communication aid can improve how physicians and patients with cancer discuss the diagnosis. The aid, completed before the consultation, summarizes the patient's disclosure preferences and questions. Researchers will compare outcomes like patie…
Phase: NA • Sponsor: Chang Gung University • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
A two-hour virtual session may help caregivers of children with cancer — a trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether a short virtual program called GOLD can reduce anxiety and boost resilience in caregivers of children recently diagnosed with cancer. About 40 caregivers will either receive the two-hour GOLD session or standard information. The study measures how many ca…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Digital navigator aims to cut financial toxicity for young adults with cancer
Symptom relief Recruiting nowThis pilot study tests a hybrid intervention that combines a digital platform (Findhelp.org) with human navigation sessions to help adolescent and young adult cancer survivors manage financial and health-related social needs. Researchers will refine the approach with input from s…
Phase: NA • Sponsor: Columbia University • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Could a homeopathic remedy ease cancer treatment fatigue?
Symptom relief Recruiting nowThis study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…
Phase: EARLY_PHASE1 • Sponsor: Beaura for Para Pharmaceutical Products Trading LLC • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Braids and conditioner may boost scalp cooling against chemo hair loss
Symptom relief Recruiting nowThis study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Can a smartphone app lift depression in cancer survivors?
Symptom relief Recruiting nowThis study compares two ways to treat depression in cancer survivors: a mobile app called Moodivate that tracks activities and mood, and 8 sessions of telehealth therapy with a mental health provider. About 45 adults who have had cancer and currently feel depressed will take part…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Could a geriatric checkup boost quality of life for older cancer survivors?
Symptom relief Recruiting nowThis study tests whether adding a geriatric assessment visit to the standard survivorship care plan improves quality of life and satisfaction for adults aged 65 and older who have completed chemotherapy with curative intent. Participants receive either the standard care plan alon…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Could an ALS drug clear the fog of chemo brain?
Symptom relief Recruiting nowThis study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Could a Steroid-Sparing cocktail tame chemo nausea?
Symptom relief Recruiting nowThis phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…
Phase: PHASE2 • Sponsor: Mahidol University • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Simple habit hacks may help cancer survivors break free from too much sitting
Symptom relief Recruiting nowThis study tests whether an 8-week habit-based program can help cancer survivors reduce the time they spend sitting or lying down during the day. Participants receive weekly tips, check-in sessions, and a Fitbit to encourage more movement. The goal is to see if the program is pra…
Phase: NA • Sponsor: University of Toronto • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Spinal pain pump may offer relief for cancer patients when opioids fail
Symptom relief Recruiting nowThis trial tests whether a small pump implanted in the abdomen that delivers pain medicine directly to the spinal fluid can improve quality of life for people with severe cancer pain that is not controlled by oral opioids. Participants are randomly assigned to get the pump or to …
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Lifestyle coaching may boost quality of life for cancer patients
Symptom relief Recruiting nowThis study tests whether a combined lifestyle program—focusing on nutrition, physical activity, sleep, stress, and sense of purpose—can improve quality of life for people with cancer. It includes cancer survivors within five years of curative treatment and those with advanced can…
Phase: NA • Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New MRI-Guided radiation aims to cut side effects in endometrial cancer
Symptom relief Recruiting nowThis study tests a new way to deliver radiation therapy for endometrial cancer using daily MRI scans to guide the beam. The goal is to give a higher dose of radiation to the tumor while sparing nearby organs like the bowel and bladder. Thirty participants will receive 15 sessions…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Online resilience training aims to ease anxiety in advanced cancer
Symptom relief Recruiting nowThis study tests a virtual group program designed to help people with advanced cancer build resilience and manage stress, anxiety, and fatigue. Participants attend seven weekly online sessions that teach techniques like mindfulness, gratitude, and reframing difficult experiences.…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Which meditation works best for cancer survivors? a new study aims to find out
Symptom relief Recruiting nowThis pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Weighted blankets may ease anxiety for cancer patients during IV therapy
Symptom relief Recruiting nowThis study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …
Phase: NA • Sponsor: Sultan Qaboos Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Cancer care goes home: study tests nurse visits to cut hospital trips
Symptom relief Recruiting nowThis study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Fish oil and band workouts: a new hope against cancer muscle loss?
Symptom relief Recruiting nowThis study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…
Phase: NA • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New writing therapy aims to ease fear in advanced cancer patients
Symptom relief Recruiting nowThis study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…
Phase: NA • Sponsor: University of Colorado, Boulder • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New program aims to boost resilience in young cancer patients
Symptom relief Recruiting nowThis study is testing a support program for teens and young adults (ages 16-30) who have just been diagnosed with cancer. The program includes a meeting with a special team and a structured course called PRISM that teaches skills like stress management and goal setting. About 130…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could a common mental health drug prevent weight loss in cancer patients?
Symptom relief Recruiting nowThis study is testing whether a low dose of olanzapine, a drug usually used for mental health conditions, can prevent or treat the loss of appetite and weight that often happens in cancer patients receiving chemotherapy. About 100 adults with stomach or ovarian cancer will take t…
Phase: PHASE3 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can talking about stress ease Cancer's mental toll? new study aims to find out
Symptom relief Recruiting nowThis study tests whether group sessions that teach stress management skills can lower distress in people with cancer. About 400 adults with cancer who have moderate distress will take part. The program helps patients recognize and reduce stress in their daily lives.
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Simple breathing and muscle relaxation techniques tested for cancer symptom relief
Symptom relief Recruiting nowThis study looks at whether two simple relaxation methods—progressive muscle relaxation and deep breathing exercises—can reduce shortness of breath and severe tiredness in people with advanced cancer receiving palliative care. About 90 participants will be assigned to one of the …
Phase: NA • Sponsor: Ankara University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
Knowledge-focused Recruiting nowThis study investigates whether measuring whole-body metabolism—how the body uses energy—can reflect the metabolic changes in ovarian tumors and predict how well patients respond to chemotherapy. Researchers will measure resting metabolic rate and other metabolic markers in women…
Sponsor: University of Tennessee Graduate School of Medicine • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Scientists track Cancer's inner workings during radiation treatment
Knowledge-focused Recruiting nowThis study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Cancer tissue bank opens to fuel research
Knowledge-focused Recruiting nowThis study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Cancer data pooling study aims to connect the dots across trials
Knowledge-focused Recruiting nowThis study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Cancer genetics study aims to personalize treatment
Knowledge-focused Recruiting nowThis study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Can we predict dangerous side effects when combining radiation and immunotherapy?
Knowledge-focused Recruiting nowThis study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a smartphone app beat cervical cancer in rural kenya?
Knowledge-focused Recruiting nowThis study is testing a mobile app called mSaada that helps community health workers educate women, track screening, and send reminders for cervical cancer screening. The trial involves 6,000 women and health workers across 12 health facilities in western Kenya. The goal is to se…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a text message help older cancer survivors move more and hurt less?
Knowledge-focused Recruiting nowThis study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
No treatment, just samples: new study aims to understand cancer immunity
Knowledge-focused Recruiting nowThis study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New decision aid aims to empower advanced cancer patients in tough treatment talks
Knowledge-focused Recruiting nowThis study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New cancer Drug's interaction with other meds under scrutiny in early trial
Knowledge-focused Recruiting nowThis early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…
Phase: PHASE1 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
What do young cancer patients really need? this survey aims to find out
Knowledge-focused Recruiting nowThis study asks 300 adolescents and young adults (ages 15-39) who have or had cancer to fill out questionnaires. The goal is to find gaps in education about exercise, sexual health, fertility, finances, and more. No treatment is given—just a survey to help improve future care.
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Tumor DNA mapping may unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…
Phase: NA • Sponsor: Ulrik Lassen • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Virtual coach aims to boost diversity in cancer trials
Knowledge-focused Recruiting nowThis study tests whether a virtual community health educator (vCHE) can increase referrals to cancer clinical trials among diverse populations. Researchers will enroll 2,000 cancer patients and their caregivers across Florida. Participants interact with a computer-based agent tha…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
HER2 test showdown: which lab method is best for chinese cancer patients?
Knowledge-focused Recruiting nowThis study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Vulvar cancer breakthrough: one test could spare women unnecessary surgery
Knowledge-focused Recruiting nowThis study is testing whether looking at two biological markers (HPV and p53) in early-stage vulvar cancer can help doctors decide the right amount of surgery. Some women may need less surgery, while others may need more. The study will follow 249 participants for 3 years to see …
Phase: NA • Sponsor: Canadian Cancer Trials Group • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
AI platform aims to unlock Real-World cancer data on a massive scale
Knowledge-focused Recruiting nowThis study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Building a better understanding of Low-Grade ovarian cancer
Knowledge-focused Recruiting nowThis study gathers medical records and leftover tissue samples from up to 2,000 people with low-grade ovarian or peritoneal tumors. The goal is to create a detailed database that helps researchers learn more about these rare cancers and how they are treated. No new drugs or proce…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Cancer drug side effects under the microscope: what do they mean?
Knowledge-focused Recruiting nowThis study tracks 170 advanced cancer patients receiving anti-VEGF therapies to record side effects and see how the disease responds. Researchers hope to find patterns linking complications to treatment success. The goal is to help doctors better understand and manage these thera…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Rare cervical cancer under the microscope: no treatment, just knowledge
Knowledge-focused Recruiting nowThis study is collecting medical records and lab results from 70 people diagnosed with a rare type of cervical cancer called clear cell carcinoma. Researchers want to understand the cancer's features and molecular profile better. No new treatments or drugs are being tested—this i…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to bridge psychosocial care gap for cancer survivors
Knowledge-focused Recruiting nowThis study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Radiation aftermath: 700 cancer patients tracked for decades
Knowledge-focused Recruiting nowThis study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
500 women with advanced uterine cancer to have tumors genetically profiled
Knowledge-focused Recruiting nowThis study looks at the genetic makeup of advanced endometrial cancer in 500 women in Russia. Researchers will test tumor samples for specific gene changes to see how common they are and what treatments patients receive. The goal is to gather information, not to test a new treatm…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New tool aims to bridge the gap in cancer conversations
Knowledge-focused Recruiting nowThis study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Large study aims to pinpoint cancer return rates and swelling risks after treatment
Knowledge-focused Recruiting nowThis study is observing about 1,715 people with early-stage endometrial cancer to see how often the cancer comes back and how often lymphedema (swelling) happens after standard treatment. Participants will have regular check-ups for 36 months. The goal is to gather real-world dat…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Can a rapid lab test guide treatment for rare gynecologic cancers?
Knowledge-focused Recruiting nowThis study explores whether a tool called SmartMatch can quickly analyze tumor tissue from standard surgeries or biopsies to suggest personalized treatment options for people with rare, advanced gynecologic cancers. The goal is to see how often SmartMatch can produce a useful tre…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Does your doctor's screen time hurt your trust? new study investigates.
Knowledge-focused Recruiting nowThis study looks at how cancer patients view their doctor's compassion, communication, and professionalism when the doctor uses an electronic health record (EHR) during the visit. About 88 adults with cancer will watch videos or fill out questionnaires. The goal is to understand …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Heart risk after chemo: scientists hunt for clues in your blood
Knowledge-focused Recruiting nowThis study is trying to understand why some people who get chemotherapy for cancer later develop heart issues, while others don't. Researchers will collect blood samples from 1,000 adults who have had chemotherapy, including those who had heart problems and those who didn't. By s…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
AI chatbot could guide cancer patients through confusing health info
Knowledge-focused Recruiting nowThis study looks at how people with endometrial cancer find medical information and how satisfied they are with it. Researchers will also ask patients if they'd be interested in using an AI-powered educational tool. The goal is to understand current needs and see if AI could help…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New biobank aims to unlock secrets of Immunotherapy's harsh side effects
Knowledge-focused Recruiting nowThis study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
AI translates medical scans into plain english for cancer patients
Knowledge-focused Recruiting nowThis study is testing a new AI tool that creates patient-friendly summaries of radiology reports for people with cancer. The goal is to see if these easy-to-read summaries help patients better understand their scan results and reduce the number of questions doctors receive. About…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Chatbot vs. standard care: which boosts genetic testing in young cancer patients?
Knowledge-focused Recruiting nowThis study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Could vitamin d predict cervical cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at whether vitamin D levels in the blood and cervical fluid before treatment can predict how well chemoradiotherapy works for locally advanced cervical cancer. Researchers will measure vitamin D in 100 women undergoing standard treatment and track their response …
Sponsor: University of Kragujevac • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Brazil launches major study to map ovarian cancer treatment gaps
Knowledge-focused Recruiting nowThis observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insig…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New survey aims to give young cancer patients a stronger voice
Knowledge-focused Recruiting nowThis study is testing a new questionnaire called PRO-AYA, designed to measure quality of life in adolescents and young adults (ages 15-39) with cancer. Researchers want to see if the survey is reliable and accurate, including a Spanish version. 120 participants will fill out the …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can a smartwatch help track cancer symptoms? small study aims to find out
Knowledge-focused Recruiting nowThis study is testing whether people in early-phase cancer trials will consistently wear a smartwatch and complete weekly symptom surveys on a phone app. Thirty participants will use the devices for 4 weeks. The goal is to see if this approach is practical and acceptable, not to …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists launch massive tumor repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists try to personalize heated chemo for stomach cancers
Knowledge-focused Recruiting nowThis study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can exercise boost brain power in young cancer survivors?
Knowledge-focused Recruiting nowThis study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists hunt for hidden cancer clues in families
Knowledge-focused Recruiting nowThis study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind hereditary cancers
Knowledge-focused Recruiting nowThis study collects tissue samples, medical data, and family histories from over 1,100 people being screened for colorectal or endometrial cancer. Researchers hope to discover new genes and mechanisms that increase cancer risk, especially in hereditary cancer syndromes. The goal …
Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
New study tracks sleep problems after cancer diagnosis
Knowledge-focused Recruiting nowThis study follows 260 adults newly diagnosed with cancer who have no prior sleep issues. Researchers will track how insomnia develops over the first year, using questionnaires to measure sleep quality and severity. The goal is to understand what factors—like treatment type or em…
Sponsor: Centre Hospitalier Emile Roux • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can modern Radiotherapy's late effects be predicted?
Knowledge-focused Recruiting nowThis study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Reading Cancer's genetic playbook: a quest to match patients to the right experimental therapy
Knowledge-focused Recruiting nowThis observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
Knowledge-focused Recruiting nowThis trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can chemo and radiation steal fertility? a massive study aims to find out
Knowledge-focused Recruiting nowThis observational study tracks 7,000 men and women with cancer to see how treatments like chemotherapy, radiation, and immunotherapy affect fertility. In women, researchers measure a hormone called AMH to gauge ovarian reserve; in men, they analyze sperm quality. The goal is to …
Sponsor: Michael von Wolff • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Learning from loss: study seeks to improve tough talks in pediatric cancer
Knowledge-focused Recruiting nowThis study interviews bereaved parents and oncologists to understand how they discussed uncertainty during a child's cancer treatment. The goal is to find better ways for doctors and families to communicate about what the future may hold. Participants include parents whose child …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Could centralized surgery boost ovarian cancer survival?
Knowledge-focused Recruiting nowThis study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian ca…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Building a biobank to unlock radiation Therapy's secrets
Knowledge-focused Recruiting nowThis research study collects tissue samples and medical information from people with cancer who are receiving radiation therapy, as well as from healthy volunteers. The goal is to create a long-term resource that scientists can use to study how cancer responds to radiation and to…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
What happens to young cancer patients after treatment? major study investigates
Knowledge-focused Recruiting nowThis study follows thousands of young adults (aged 18–40) diagnosed with solid tumors to see how their treatment affects organ preservation, fertility, and long-term quality of life. Researchers will compare them with older patients to understand unique needs. The goal is to impr…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Smartphone app aims to capture cancer patients' diets during radiation
Knowledge-focused Recruiting nowThis study tests whether cancer patients undergoing radiation therapy can use a mobile app called myCircadian Clock to record everything they eat and drink (except water and medications). Twenty adults starting radiation for cancer will use the app throughout their treatment. The…
Phase: NA • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Scientists probe hidden clues to immunotherapy success in endometrial cancer
Knowledge-focused Recruiting nowThis study investigates why some advanced or recurrent endometrial cancers respond to immunotherapy while others do not. Researchers will collect tumor samples from 510 patients before they start immunotherapy and use lab-grown tumor models to study molecular and genetic features…
Phase: NA • Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
What do ovarian cancer survivors really need? a new study aims to find out
Knowledge-focused Recruiting nowThis study surveys 2,000 ovarian cancer survivors to identify their ongoing concerns and unmet needs after diagnosis. Participants complete a one-time survey about their experiences, and up to 40 will also take part in a follow-up interview. The goal is to understand what matters…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Can daily activity ease fatigue in cancer survivors? a new study investigates
Knowledge-focused Recruiting nowThis study looks at how daily physical activity is linked to fatigue in people who have finished or are finishing cancer treatment. Participants wear a small activity monitor and report their fatigue levels. The goal is to understand whether being more active might help reduce fa…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Bacteria in the mouth and gut may predict who responds to cancer immunotherapy
Knowledge-focused Recruiting nowThis study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
New robot arm takes on cancer surgery – first safety check begins
Knowledge-focused Recruiting nowThis study will test a new robotic surgery platform called RonovoTM in 40 adults with cancer who need elective surgery. The robot helps surgeons perform minimally invasive procedures in digestive, thoracic, urology, and gynecology areas. Researchers will track complications, tech…
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Thousands of cancer patients enrolled in massive immunotherapy observation study
Knowledge-focused Recruiting nowThis study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive proton therapy registry aims to unlock secrets of cancer treatment
Knowledge-focused Recruiting nowThis registry collects detailed information from cancer patients treated with proton radiation therapy. Researchers will track treatment plans, side effects, and quality of life over 15 years. The goal is to learn which patients benefit most from this precise form of radiation an…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Could your genes hold the key to cancer risk? scientists investigate families
Knowledge-focused Recruiting nowThis study looks at genetic and behavioral factors that might influence cancer development and outcomes. It involves people with a personal or family history of cancer, who provide samples like blood, saliva, or urine. The goal is to better understand inherited cancer risks and f…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood test may guide cancer care without biopsy
Knowledge-focused Recruiting nowThis study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Cancer Patients' supplement use under the microscope
Knowledge-focused Recruiting nowThis observational study will survey 1,000 cancer patients about their use of dietary supplements like vitamins, minerals, and herbal products. Researchers want to know how common supplement use is, whether patients experience side effects, and if these supplements could interact…
Sponsor: Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New italian tool aims to ease MRI anxiety for cancer patients
Knowledge-focused Recruiting nowThis study is translating and testing an Italian version of a questionnaire that measures anxiety in cancer patients during whole-body MRI scans. Researchers will enroll 175 adult cancer patients at the European Institute of Oncology. The goal is to ensure the Italian version is …
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New PET imaging study aims to sharpen tumor detection
Knowledge-focused Recruiting nowThis study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participa…
Sponsor: University Hospital, Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New registry aims to learn from Real-World retreatment of gynecologic cancers
Knowledge-focused Recruiting nowThis observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …
Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could a chatbot help close the gap in genetic cancer testing?
Knowledge-focused Recruiting nowThis study compares a smartphone chatbot to usual care for collecting family history and identifying women at high risk for hereditary cancer syndromes. Participants are English-speaking gynecology patients aged 18 and older who have not had prior genetic testing. The goal is to …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Cancer pill makeover may mess with treatment adherence
Knowledge-focused Recruiting nowThis study follows 334 cancer patients to see if switching between different-looking generic chemo pills affects their adherence and health outcomes. Researchers will track pill counts and patient surveys over six months. The goal is to understand if changes in pill color, shape,…
Sponsor: Universidad Miguel Hernandez de Elche • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Protein clues may predict cervical cancer return
Knowledge-focused Recruiting nowThis study is looking at 180 women with advanced cervical cancer who were treated with radiation and chemotherapy. Researchers want to see if high levels of certain proteins (called IAPs) in the original tumor biopsy can predict whether the cancer will come back within two years.…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to uncover why some women have worse sexual side effects from radiation
Knowledge-focused Recruiting nowThis study is observing 300 women with female sexual organs who are receiving radiotherapy for certain cancers. Researchers want to understand why some patients have more sexual side effects than others. They will track sexual quality of life and look at radiation doses to find p…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Gene-Guided cancer therapy: a new hope for advanced tumors?
Knowledge-focused Recruiting nowThis study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…
Sponsor: Seoul National University Bundang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Decoding Immunotherapy's liver side effect to keep cancer treatment on track
Knowledge-focused Recruiting nowThis study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Question list may empower gynecologic cancer patients in clinic
Knowledge-focused Recruiting nowThis study tests whether giving gynecologic cancer patients a list of questions to ask their doctor improves their confidence, reduces distress, and builds trust. About 70 adults with newly diagnosed or suspected gynecologic cancer will either receive the question list or usual c…
Phase: NA • Sponsor: Ira Winer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Million-Patient study aims to unravel cancer fatigue mystery
Knowledge-focused Recruiting nowThis study will follow 1 million Chinese adults with cancer to measure how common and severe cancer-related fatigue is. Researchers will look at what factors influence fatigue and how it affects treatment and survival. The goal is to better understand this common but often overlo…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to unravel cancer blood clot mysteries
Knowledge-focused Recruiting nowThis study is collecting blood and urine samples from 150 cancer patients who have had blood clots. The goal is to learn more about why clots happen in cancer and how to prevent them. Participants will be followed over time to track clot recurrence and bleeding risks.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Mayo clinic launches study to grow tumors in the lab
Knowledge-focused Recruiting nowThis study collects tumor tissue, blood, and cheek swabs from 50 adults with cancer to create personalized 3D models in the lab. Researchers will analyze the genetics and drug responses of these models to find new treatment targets. The goal is to improve understanding of aggress…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive global study aims to uncover why young cancer patients in poorer nations fare worse
Knowledge-focused Recruiting nowThis study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…
Sponsor: Resonance, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Cancer gene study aims to unlock prognosis secrets
Knowledge-focused Recruiting nowThis study is collecting medical data and tumor or blood samples from 500 adults with malignant tumors treated at a Chinese hospital between 2017 and 2025. Researchers will analyze genes, immune cells, and other molecular features to understand what affects survival and treatment…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC